Global Injectable Drug Delivery Market Size, Trends and Forecast to 2024
©
Global injectable drug delivery is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024
Request for Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market
The major factors driving the growth of this market are the increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. On the other hand, safety concerns regarding the use of injectables, increased risk of blood-borne infections due to injectables, and presence of other drug delivery methods (such as oral and transdermal) may hinder the growth of the market.
The global injectable drug delivery market is segmented on the basis of type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography.
Browse Full Report with Details TOC @ http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/
On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others.
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.
Based on geography, the market is segmented into five geographical regions:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa.
The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.
Some of the major factors driving the market for injectable drug delivery market are increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. Increasing prevalence of chronic diseases, rising demand for self-injection devices, growth of the biologics, and technological advancements are the major factors driving the growth of the injectable drug delivery market.
Some of the major players operating in this market are
• Pfizer and Baxter International, Inc.,
• Gerresheimer AG,
• Schott AG,
• Alkermes Plc.,
• Eli Lilly and Company,
• Sandoz,
• Terumo Corporation,
• Teva Pharmaceuticals Industries Ltd.,
• Bespak,
• Antares Pharma,
• Elcam Medical,
• Haselmeier,
• Mylan N.V.,
• Novo Nordisk,
• Owen Mumford Ltd,
• Sanofi,
• West Pharmaceutical Services, Inc,
• Ypsomed Holding AG
Inquiry before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market
Table Of Content:
1. INTRODUCTION
1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
4.3.2. RESTRAINTS
4.3.3. OPPORTUNITIES
4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES
4.3.4. THREATS
4.3.4.1. PRODUCT RECALLS
4.3.4.2. REGULATORY HURDLES
4.3.4.3. STABILITY OF PRODUCTS
4.3.4.4. STERILITY OF INJECTIONS
4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. INJECTABLE DRUG DELIVERY DEVICES
5.3. INJECTABLE DRUG DELIVERY FORMULATIONS
6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.2.1. BY MATERIAL
6.2.1.1. GLASS
6.2.1.2. PLASTIC
6.2.2. BY PRODUCT
6.2.2.1. EMPTY SYRINGES
6.2.2.2. PREFILLED SYRINGES
6.2.3. BY USABLITY
6.2.3.1. REUSABLE SYRINGES
6.2.3.2. DISPOSABLE SYRINGES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTORS
6.3.1.1. BY PRODUCT
6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS
6.3.1.2. BY TECHNOLOGY
6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
6.3.1.3. BY USABILITY
6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
6.3.2. AUTOINJECTORS
6.3.2.1. BY PRODUCT
6.3.2.1.1. EMPTY AUTOINJECTORS
6.3.2.1.2. PREFILLED AUTOINJECTORS
6.3.2.2. BY TECHNOLOGY
6.3.2.2.1. AUTOMATED AUTOINJECTORS
6.3.2.2.2. MANUAL AUTOINJECTORS
6.3.2.3. BY DESIGN
6.3.2.3.1. STANDARDIZED AUTOINJECTORS
6.3.2.3.2. CUSTOMIZED AUTOINJECTORS
6.3.2.4. BY USABILITY
6.3.2.4.1. REUSABLE AUTOINJECTORS
6.3.2.4.2. DISPOSABLE AUTOINJECTORS
6.3.3. PEN INJECTORS
6.3.3.1. BY PRODUCT
6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS
6.3.3.2. BY DESIGN
6.3.3.2.1. STANDARDIZED PEN INJECTORS
6.3.3.2.2. CUSTOMIZED PEN INJECTORS
6.3.3.3. BY USABILITY
6.3.2.3.1. REUSABLE PEN INJECTORS
6.3.2.3.2. DISPOSABLE PEN INJECTORS
6.3.4. WEARABLE INJECTORS
6.3.5. OTHER INJECTABLE DEVICES
7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.2.1. SOLUTIONS
7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.2.3. SUSPENSIONS
7.2.4. EMULSIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
7.3.1. COLLOIDAL DISPERSIONS
7.3.1.1. LIPOSOMES
7.3.1.2. NIOSOMES
7.3.1.3. POLYMERIC MIXED MICELLES
7.3.1.4. NANOPARICLES
7.3.1.4.1. NANOSUSPENSIONS
7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS
7.3.1.4.3. SOLID LIPID NANOPARTICLES
7.3.2. MICROPARTICLES
7.3.2.1. MICROSPHERES
7.3.2.2. MICROCAPSULES
7.3.3. LONG ACTING INJECTION FORMULATIONS
8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.2.1. RHEUMATOID ARTHRITIS
8.2.2. MULTIPLE SCLEROSIS
8.2.3. CHRON’S DISEASE
8.2.4. PSORIASIS
8.2.5. OTHER AUTOIMMUNE DISEASES
8.3. HORMONAL DISORDERS
8.3.1. DIABETES
8.3.2. ANEMIA
8.3.3. REPRODUCTIVE HEALTH DISEASE
8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. OSTEOPOROSIS
8.3.6. GROWTH HORMONE DEFICIENCY (GHD)
8.4. ORPHAN DISEASES
8.5. ONCOLOGY
8.6. OTHERS
8.6.1. PAIN MANAGEMENT
8.6.2. ALERGY TREATMENT
8.6.3. AESTHETIC TREATMENTS
8.6.4. HEPATITIS C
8.6.5. HEMOPHILIA
9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
12.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
12.1.1. NORTH AMERICA
12.1.1.1. U.S.
12.1.1.2. CANADA
12.1.1.3. MEXICO
12.1.2. EUROPE
12.1.2.1. GERMANY
12.1.2.2. FRANCE
12.1.2.3. U.K.
12.1.2.4. ITALY
12.1.2.5. SPAIN
12.1.2.6. RUSSIA
12.1.2.7. TURKEY
12.1.2.8. BELGIUM
12.1.2.9. NETHERLANDS
12.1.2.7. SWITZERLAND
12.1.2.8. REST OF EUROPE
12.1.3. ASIA-PACIFIC (APAC)
12.1.3.1. JAPAN
12.1.3.2. CHINA
12.1.3.3. SOUTH KOREA
12.1.3.4. INDIA
12.1.3.5. AUSTRALIA
12.1.3.6. SINGAPORE
12.1.3.7. THAILAND
12.1.3.8. MALAYSIA
12.1.3.9. INDONESIA
12.1.3.10. PHILIPPINES
12.1.3.11. REST OF APAC
12.1.4. LATIN AMERICA
12.1.4.1. BRAZIL
12.1.4.2. REST OF LATIN AMERICA
12.1.5. MIDDLE EAST AND AFRICA
12.1.5.1. SOUTH AFRICA
12.1.5.2. REST OF MIDDLE EAST AND AFRICA
12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.7. MERGERS & ACQUISITIONS
13.8. NEW PRODUCT DEVELOPMENT & APPROVALS
13.9. EXPANSIONS
13.10. REGULATORY CHANGES
13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
14.1. BAXTER INTERNATIONAL, INC.
14.1.1. OVERVIEW
14.1.2. SWOT ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. REVENUE ANALYSIS
14.1.5. ANALYSTS VIEW
14.2. BECTON, DICKINSON AND COMPANY
14.2.1. OVERVIEW
14.2.2. SWOT ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. REVENUE ANALYSIS
14.2.5. ANALYSTS VIEW
14.3. GERRESHEIMER, AG
14.3.1. OVERVIEW
14.3.2. SWOT ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. REVENUE ANALYSIS
14.3.5. ANALYST VIEW
14.4. PFIZER, INC.
14.4.1. OVERVIEW
14.4.2. SWOT ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. REVENUE ANALYSIS
14.4.5. ANALYSTS VIEW
14.5. SCHOTT AG
14.5.1. OVERVIEW
14.5.2. SWOT ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. REVENUE ANALYSIS
14.5.5. ANALYSTS VIEW
14.6. ALKERMES PLC
14.6.1. OVERVIEW
14.6.2. SWOT ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. REVENUE ANALYSIS
14.6.5. ANALYSTS VIEW
14.7. ELI LILLY AND COMPANY
14.7.1. OVERVIEW
14.7.2. SWOT ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. REVENUE ANALYSIS
14.7.5. ANALYSTS VIEW
14.8. SANDOZ
14.8.1. OVERVIEW
14.8.2. SWOT ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. REVENUE ANALYSIS
14.8.5. ANALYSTS VIEW
14.9. TERUMO CORPORATION
14.9.1. OVERVIEW
14.9.2. SWOT ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. REVENUE ANALYSIS
14.9.5. ANALYSTS VIEW
14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.10.1. OVERVIEW
14.10.2. SWOT ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. REVENUE ANALYSIS
14.10.5. ANALYSTS VIEW
15. APPENDIX
15.1. RELATED REPORTS
15.2. CUSTOMIZABLE OPTIONS
15.3. SOURCE SHEET
15.4. BIBLIOGRAPHY
16. ABOUT DATA BRIDGE MARKET RESEARCH
Related Report
North America Diabetes Care Devices Market – Industry Trends and Forecast to 2024
North America Diabetes Care Devices Market By Product Type, By End-User, By Distribution Channel, By Country (U.S., Canada, Mexico)- Industry Trends and Forecast to 2024
http://databridgemarketresearch.com/reports/north-america-diabetes-care-devices-market/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog http://databridgemarketresearch.com/blog/
Request for Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market
The major factors driving the growth of this market are the increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. On the other hand, safety concerns regarding the use of injectables, increased risk of blood-borne infections due to injectables, and presence of other drug delivery methods (such as oral and transdermal) may hinder the growth of the market.
The global injectable drug delivery market is segmented on the basis of type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography.
Browse Full Report with Details TOC @ http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/
On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others.
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others.
Based on geography, the market is segmented into five geographical regions:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa.
The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.
Some of the major factors driving the market for injectable drug delivery market are increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. Increasing prevalence of chronic diseases, rising demand for self-injection devices, growth of the biologics, and technological advancements are the major factors driving the growth of the injectable drug delivery market.
Some of the major players operating in this market are
• Pfizer and Baxter International, Inc.,
• Gerresheimer AG,
• Schott AG,
• Alkermes Plc.,
• Eli Lilly and Company,
• Sandoz,
• Terumo Corporation,
• Teva Pharmaceuticals Industries Ltd.,
• Bespak,
• Antares Pharma,
• Elcam Medical,
• Haselmeier,
• Mylan N.V.,
• Novo Nordisk,
• Owen Mumford Ltd,
• Sanofi,
• West Pharmaceutical Services, Inc,
• Ypsomed Holding AG
Inquiry before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market
Table Of Content:
1. INTRODUCTION
1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
4.3.2. RESTRAINTS
4.3.3. OPPORTUNITIES
4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES
4.3.4. THREATS
4.3.4.1. PRODUCT RECALLS
4.3.4.2. REGULATORY HURDLES
4.3.4.3. STABILITY OF PRODUCTS
4.3.4.4. STERILITY OF INJECTIONS
4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. INJECTABLE DRUG DELIVERY DEVICES
5.3. INJECTABLE DRUG DELIVERY FORMULATIONS
6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.2.1. BY MATERIAL
6.2.1.1. GLASS
6.2.1.2. PLASTIC
6.2.2. BY PRODUCT
6.2.2.1. EMPTY SYRINGES
6.2.2.2. PREFILLED SYRINGES
6.2.3. BY USABLITY
6.2.3.1. REUSABLE SYRINGES
6.2.3.2. DISPOSABLE SYRINGES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTORS
6.3.1.1. BY PRODUCT
6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS
6.3.1.2. BY TECHNOLOGY
6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
6.3.1.3. BY USABILITY
6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
6.3.2. AUTOINJECTORS
6.3.2.1. BY PRODUCT
6.3.2.1.1. EMPTY AUTOINJECTORS
6.3.2.1.2. PREFILLED AUTOINJECTORS
6.3.2.2. BY TECHNOLOGY
6.3.2.2.1. AUTOMATED AUTOINJECTORS
6.3.2.2.2. MANUAL AUTOINJECTORS
6.3.2.3. BY DESIGN
6.3.2.3.1. STANDARDIZED AUTOINJECTORS
6.3.2.3.2. CUSTOMIZED AUTOINJECTORS
6.3.2.4. BY USABILITY
6.3.2.4.1. REUSABLE AUTOINJECTORS
6.3.2.4.2. DISPOSABLE AUTOINJECTORS
6.3.3. PEN INJECTORS
6.3.3.1. BY PRODUCT
6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS
6.3.3.2. BY DESIGN
6.3.3.2.1. STANDARDIZED PEN INJECTORS
6.3.3.2.2. CUSTOMIZED PEN INJECTORS
6.3.3.3. BY USABILITY
6.3.2.3.1. REUSABLE PEN INJECTORS
6.3.2.3.2. DISPOSABLE PEN INJECTORS
6.3.4. WEARABLE INJECTORS
6.3.5. OTHER INJECTABLE DEVICES
7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.2.1. SOLUTIONS
7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.2.3. SUSPENSIONS
7.2.4. EMULSIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
7.3.1. COLLOIDAL DISPERSIONS
7.3.1.1. LIPOSOMES
7.3.1.2. NIOSOMES
7.3.1.3. POLYMERIC MIXED MICELLES
7.3.1.4. NANOPARICLES
7.3.1.4.1. NANOSUSPENSIONS
7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS
7.3.1.4.3. SOLID LIPID NANOPARTICLES
7.3.2. MICROPARTICLES
7.3.2.1. MICROSPHERES
7.3.2.2. MICROCAPSULES
7.3.3. LONG ACTING INJECTION FORMULATIONS
8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.2.1. RHEUMATOID ARTHRITIS
8.2.2. MULTIPLE SCLEROSIS
8.2.3. CHRON’S DISEASE
8.2.4. PSORIASIS
8.2.5. OTHER AUTOIMMUNE DISEASES
8.3. HORMONAL DISORDERS
8.3.1. DIABETES
8.3.2. ANEMIA
8.3.3. REPRODUCTIVE HEALTH DISEASE
8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. OSTEOPOROSIS
8.3.6. GROWTH HORMONE DEFICIENCY (GHD)
8.4. ORPHAN DISEASES
8.5. ONCOLOGY
8.6. OTHERS
8.6.1. PAIN MANAGEMENT
8.6.2. ALERGY TREATMENT
8.6.3. AESTHETIC TREATMENTS
8.6.4. HEPATITIS C
8.6.5. HEMOPHILIA
9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
12.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
12.1.1. NORTH AMERICA
12.1.1.1. U.S.
12.1.1.2. CANADA
12.1.1.3. MEXICO
12.1.2. EUROPE
12.1.2.1. GERMANY
12.1.2.2. FRANCE
12.1.2.3. U.K.
12.1.2.4. ITALY
12.1.2.5. SPAIN
12.1.2.6. RUSSIA
12.1.2.7. TURKEY
12.1.2.8. BELGIUM
12.1.2.9. NETHERLANDS
12.1.2.7. SWITZERLAND
12.1.2.8. REST OF EUROPE
12.1.3. ASIA-PACIFIC (APAC)
12.1.3.1. JAPAN
12.1.3.2. CHINA
12.1.3.3. SOUTH KOREA
12.1.3.4. INDIA
12.1.3.5. AUSTRALIA
12.1.3.6. SINGAPORE
12.1.3.7. THAILAND
12.1.3.8. MALAYSIA
12.1.3.9. INDONESIA
12.1.3.10. PHILIPPINES
12.1.3.11. REST OF APAC
12.1.4. LATIN AMERICA
12.1.4.1. BRAZIL
12.1.4.2. REST OF LATIN AMERICA
12.1.5. MIDDLE EAST AND AFRICA
12.1.5.1. SOUTH AFRICA
12.1.5.2. REST OF MIDDLE EAST AND AFRICA
12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.7. MERGERS & ACQUISITIONS
13.8. NEW PRODUCT DEVELOPMENT & APPROVALS
13.9. EXPANSIONS
13.10. REGULATORY CHANGES
13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
14.1. BAXTER INTERNATIONAL, INC.
14.1.1. OVERVIEW
14.1.2. SWOT ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. REVENUE ANALYSIS
14.1.5. ANALYSTS VIEW
14.2. BECTON, DICKINSON AND COMPANY
14.2.1. OVERVIEW
14.2.2. SWOT ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. REVENUE ANALYSIS
14.2.5. ANALYSTS VIEW
14.3. GERRESHEIMER, AG
14.3.1. OVERVIEW
14.3.2. SWOT ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. REVENUE ANALYSIS
14.3.5. ANALYST VIEW
14.4. PFIZER, INC.
14.4.1. OVERVIEW
14.4.2. SWOT ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. REVENUE ANALYSIS
14.4.5. ANALYSTS VIEW
14.5. SCHOTT AG
14.5.1. OVERVIEW
14.5.2. SWOT ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. REVENUE ANALYSIS
14.5.5. ANALYSTS VIEW
14.6. ALKERMES PLC
14.6.1. OVERVIEW
14.6.2. SWOT ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. REVENUE ANALYSIS
14.6.5. ANALYSTS VIEW
14.7. ELI LILLY AND COMPANY
14.7.1. OVERVIEW
14.7.2. SWOT ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. REVENUE ANALYSIS
14.7.5. ANALYSTS VIEW
14.8. SANDOZ
14.8.1. OVERVIEW
14.8.2. SWOT ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. REVENUE ANALYSIS
14.8.5. ANALYSTS VIEW
14.9. TERUMO CORPORATION
14.9.1. OVERVIEW
14.9.2. SWOT ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. REVENUE ANALYSIS
14.9.5. ANALYSTS VIEW
14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.10.1. OVERVIEW
14.10.2. SWOT ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. REVENUE ANALYSIS
14.10.5. ANALYSTS VIEW
15. APPENDIX
15.1. RELATED REPORTS
15.2. CUSTOMIZABLE OPTIONS
15.3. SOURCE SHEET
15.4. BIBLIOGRAPHY
16. ABOUT DATA BRIDGE MARKET RESEARCH
Related Report
North America Diabetes Care Devices Market – Industry Trends and Forecast to 2024
North America Diabetes Care Devices Market By Product Type, By End-User, By Distribution Channel, By Country (U.S., Canada, Mexico)- Industry Trends and Forecast to 2024
http://databridgemarketresearch.com/reports/north-america-diabetes-care-devices-market/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog http://databridgemarketresearch.com/blog/